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Objectives:
 
To investigate how indirect costs are evalu-
ated in pharmacoeconomic studies in Italy and the atti-
tude of Italian pharmacoeconomists toward indirect costs.
 
Methods:
 
A literature review was conducted, specifi-
cally focused on pharmacoeconomic studies including
indirect costs carried out in Italy, and a suevey among
Italian pharmacoeconomics experts.
 
Results:
 
Nineteen studies were available for review. Al-
though the methods used to calculate the value of pro-
duction loss due to morbidity were all based on the
Human Capital Approach (HCA), there was a wide
variability among studies in practical methods. The pa-
rameters used to value production losses varied widely
too. Of the 25 survey responders, 20 considered it im-
portant to include indirect costs in pharmacoeconomic
studies; 56% of those interviewed stated that health au-
thorities should require indirect cost evaluations. Most
of these experts would include indirect cost estimates in
drug-pricing calculation.
 
Conclusions:
 
In Italy studies evaluating indirect costs
are still only few, although there is evidence of an in-
crease. Italian pharmacoeconomists are far from reach-
ing any consensus on methods for evaluating these
costs. Methods need to be standardized particularly
with respect to the parameters used to quantify produc-
tive time lost in monetary terms.
 
Keywords:
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Introduction
 
In recent years economic evaluations of pharma-
ceuticals have become more frequent [1]. In some
countries—Australia, Canada, and, this year, the
Netherlands—pharmacoeconomic studies are man-
datory for pricing and reimbursement. Also, in-
dustry is being encouraged to provide pharma-
coeconomic evidence on new drugs, and many
countries have issued guidelines [2]. However,
many methodological issues—e.g., use of model-
ing, and inclusion of indirect costs—are still de-
bated and are currently the topic of widespread
research. Each country’s attitude toward pharma-
coeconomic studies depends on a number of points
such as the institutional framework (i.e., type of
health care system), the approach to pricing and
reimbursement of pharmaceuticals, and more gen-
erally the social security arrangements. For exam-
ple, in some countries social security payments
come from the same budget as health care; in oth-
ers they don’t. Hence, the attitude toward indirect
costs is also likely to vary in each country.
We investigated how indirect costs are evalu-
ated in pharmacoeconomic studies conducted in
Italy. The aim was to analyze how, in practice, in-
direct costs are assessed in economic evaluation
studies, with the intention of providing informa-
tion on how Italian researchers deal with this is-
sue, rather than assessing the theoretical strengths
and weaknesses of different methods.
This article is composed of two parts. The first
describes briefly the existing methods for assessing
indirect costs and the recommendations of pharma-
coeconomics methodological guidelines issued by
public authorities. It also provides a brief back-
ground of the Italian pharmacoeconomics context.
The second part analyzes the methods used in the
Italian studies reviewed and presents the results of
a survey conducted among Italian pharmacoeco-
nomics experts. A final discussion closes the article.
 
Evaluation of Indirect Costs
 
The economic costs of disease are normally di-
vided into direct, indirect, and intangible costs [3].
Direct costs are the value of resources used to pre-
vent, detect, and treat a health impairment or its
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effects [4]. Indirect costs are the value of produc-
tion lost to society due to absence from work, dis-
ability, and death [4]. Since indirect costs do not
directly influence expenditures for treating dis-
ease, they are not easily measurable. However, in-
direct costs often strongly influence the result of
economic evaluations of health care programs [4].
In fact, according to one review of studies includ-
ing indirect costs of diseases, these costs amounted
on average to 52% of the total costs, or the total
costs saved by health care interventions [4,5].
Intangible costs relate to the nonmonetary con-
sequences that are by definition difficult to mea-
sure and assess, such as pain and suffering associ-
ated with the disease. They are not usually included
in economic evaluations, but they are captured in-
directly through quality-of-life scales [3].
Indirect cost evaluation methodology is still de-
bated. Basic methods have been developed and
variations have been recently proposed. It is not
the purpose of this article to assess the appropri-
ateness of methods for evaluating indirect costs.
However, a preliminary brief description of the
approaches—the Human Capital Approach (HCA);
its variation, Friction Cost Method (FCM); and
the Health State Valuation (HSV)—seems to be
useful.
According to the HCA, indirect costs are esti-
mated as the gross income lost during the time of
absence from work. The calculation is usually
based on per capita average wages obtained from
national or population surveys [6]. There are
many difficulties with the HCA. First, people out-
side the labor force, such as students, homemak-
ers, and the elderly, are discriminated against [6].
Second, wage rates may reflect inequities due to
labor market imperfections [3]. In addition, esti-
mates based on HCA are often higher than the
real indirect costs because of the extra labor avail-
able within firms and replacement of sick employ-
ees by unemployed [6,7] since full employment in
the labor market is not realistic. As a consequence,
Koopmanschap et al. [8] proposed a variation of
HCA, the FCM, based on the idea that the
amount of production lost due to illness depends
on the time organizations need to restore the ini-
tial level of production (friction period) [3]. Thus,
according to the FCM, the price of labor is set to
zero after the friction period. There are theoretical
and empirical problems with the FCM too. First,
adoption of the FCM would imply a different ap-
proach for direct cost estimates as well. As some
authors argue [7], if it is the case that the opportu-
nity cost of additional labor is close to zero, the
part of direct costs generated by labor should be
set close to zero in any economic evaluation of a
health care program based on FCM. Moreover,
the FCM requires a huge amount of information.
To assess the cost of lost production, the length of
the friction period and the value of the elasticity
for annual labor time versus labor productivity
are needed. Unfortunately, these data are unlikely
to be available at country level.
With HSV methods, indirect costs are repre-
sented by the value of utility (i.e., QALYs) or wel-
fare (Willingness to Pay) lost due to illness. Assess-
ing health states as a whole, these approaches also
include intangibles, such as pain, discomfort, and
suffering, that are not directly related to produc-
tion losses. Some authors thus suggest considering
these items as health effects and quantify them in
terms of reduced quality of life [9]. Accordingly,
their use in assessing indirect costs must be consid-
ered with caution, since individual evaluation of
health states included in the denominator of cost-
consequences ratios could capture the time cost as
well [10], generating a “double counting” problem.
 
Methodological Guidelines and Indirect Costs.
 
Canada, the Canadian Province of Ontario, Aus-
tralia, and recently the Netherlands have issued
methodological guidelines for pharmacoeconomic
studies to be submitted for reimbursement proce-
dures for new drugs. These countries require phar-
maceutical companies to produce pharmacoeco-
nomic evidence for new drugs in order to obtain
reimbursement by the health authorities. The Ca-
nadian guidelines [11] accept the inclusion of indi-
rect costs in economic evaluation studies provided
they are clearly separated from direct costs, but
they do not give any methodological recommen-
dation on the methods for quantifying them. The
guidelines of Ontario [12] only mention social
costs as an important component of economic
evaluation. In the Australian guidelines [13] inclu-
sion of indirect costs is discouraged. The more re-
cent Dutch guidelines [14] are the only ones that
explicitly suggest incorporating indirect costs, keep-
ing them separate from direct ones. The Dutch guide-
lines are also the only ones recommending a
specific evaluation method—the FCM.
 
Italian Background
 
In Italy, one of the biggest pharmaceutical markets
in Europe, the National Health Service, provides
universal coverage and comprehensive health care
free at the point of delivery [15]. Pharmaceutical
prices are set on the basis of comparisons with
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other European Union countries, although the
level of reimbursement is related to the clinical im-
portance assigned to the drug by the National
Drugs Committee (Commissione Unica del Far-
maco, CUF) [16,17].
CUF lists pharmacoeconomics as one of the
subjects to be considered in submitting approval
dossiers for innovative drugs. The Italian Commit-
tee for Economic Planning (Comitato Interminis-
teriale Pianificazione Economica, CIPE) also men-
tions cost-effectiveness ratios as a main criterion
for pricing negotiations of innovative drugs [2].
As a consequence, the number of economic evalu-
ation studies in Italy has risen steeply in the last
few years, and research groups have been set up,
involved in economic evaluation of health care
programs. Almost all the Italian subsidiaries of the
major pharmaceutical companies have introduced
pharmacoeconomics as a management task [18].
Three pharmacoeconomics societies (AIESET: As-
sociazione Italiana di Economia Sanitaria ed Etica;
GISF: Gruppo Italiano Studi di Farmacoecono-
mia; SIFE: Società Italiana di FarmacoEconomia)
have been founded and various methodological
guidelines have been published [19–21]. Indirect
costs are specifically addressed only in one docu-
ment [21], which recommends the human capital
approach based on gross salary for patients and
market cost of replacement for caregivers. How-
ever, the public health authorities have not yet is-
sued official guidelines and, as far as we are con-
cerned, they have not yet made any specific effort
to clarify and standardize methods.
 
Methods
 
Literature Search
 
The literature review specifically focused on Ital-
ian economic studies: We selected studies con-
ducted by Italian researchers regarding the Italian
health care system. The MEDLINE MeSH terms
 
cost benefit analysis
 
 and 
 
cost and cost analysis
 
were used to select studies published since 1992
that potentially describe cost analysis, cost of ill-
ness, cost benefit, cost utility, and cost-effective-
ness studies. The databases included MEDLINE,
NHS Economic Evaluation Database University of
York, and our internal database at the CESAV
Mario Negri Institute, which also classifies Italian
local publications and journals specialized in
health economics. Italian articles were selected by
searching for 
 
Italy, Italian
 
, and major Italian city
names. Added to these were articles in the au-
thors’ references and articles referred to in per-
sonal communications from other researchers in
the field.
 
Selection
 
First, papers with the following characteristics
were retained from the resulting list: studies con-
ducted by Italian authors and regarding the Italian
health care system, published in either English or
Italian in the period January 1992 to March 2000.
Second, we selected only cost studies: cost analy-
sis, cost of illness, cost-effectiveness, cost benefit,
or cost utility studies. Finally, we reviewed only
the studies that included and monetized indirect
costs.
 
Abstracting
 
The following items were abstracted from the se-
lected articles:
General features
• type of economic study
• disease under study
Method used to evaluate indirect costs
• inclusion of nonemployed categories
• inclusion of caregivers’ loss of production
• methods to ascertain working time lost
• valuation of production loss
 
Survey
 
A survey was conducted among Italian pharmaco-
economics experts to assess their attitude toward
indirect costs. The sample was represented by 30
experts: 15 were health economists—members of
the Italian Health Economists’ Association, Asso-
ciazione Italiana di Economisti Sanitari (AIES)—
with research interest in economic evaluation, and
15 were physicians and pharmacists, coauthors of
at least one published economic evaluation study.
This sample includes almost all the senior Italian
researchers involved in pharmacoeconomic stud-
ies. The purpose of selecting a balanced sample of
economists and noneconomists was to detect dif-
ferences in attitudes toward evaluation of indirect
costs.
The experts were mailed a questionnaire in-
cluding the following questions:
• Have you ever conducted economic studies
evaluating health care programs?
• In how many studies have you included indi-
rect costs?
• Which methods have you adopted to evaluate
indirect costs?
 Indirect Costs in Italian Pharmacoeconomics
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• Do you consider it important to calculate indi-
rect costs in economic evaluation of health
care programs? If yes, why?
• What in your opinion is the best/preferred
method for assessing indirect costs?
• Should Italian health authorities require indi-
rect costs to be incorporated in pharmacoeco-
nomic studies?
• Should pharmaceutical pricing take account of
indirect cost estimates?
 
Results
 
Literature Review of Italian Studies
 
In total, 304 articles were identified by the initial
literature search. However, 113 were not cost
studies (they were, e.g., editorials, reviews, and
methodological papers) and were rejected. Among
the remaining 191 cost studies, 172 did not include
and monetize indirect costs. Consequently, only
19 articles were eligible for review. Fifteen of these
[22–32,37–40] were cost studies, and only 4 [33–36]
were either cost-effectiveness or cost utility studies
(Table 1). Out of 19, 9 articles [22,25–27,34–36,
38,39] were published in international journals,
and all but 8 [22,23,26,29,30,37,39,40] appeared
in medical journals.
Although the methods followed to calculate the
value of production loss due to morbidity were all
based on the HCA, there was wide variability be-
tween practical methods. Only two studies [35,40]
calculated the value of production loss due to
mortality.
In nine studies [22,23,25–28,33,36,39] produc-
tion losses were calculated for both employed and
nonemployed categories, assuming that the non-
employed (e.g., housewives) also contribute to
producing services and must therefore be included
in the calculation. Eleven included production loss
for caregivers [23–27,30,31,35,36,38,39].
The parameters used to value production losses
varied widely too. Although calculation was not
always clear, only four studies used either parame-
ters found in the literature or assumptions [23,31,
33,35]. Two studies [22,40] used the average per
capita Gross Domestic Product (GDP), one [36]
the average per capita Gross National Product
(GNP), one [28] the average per capita National
Added Value (NAV) (i.e., GDP minus indirect taxes
on added value and imports), one [30] the average
per capita Gross Regional Product (GRP) of the re-
gion where the study was conducted, and one the
Minimum Wage (MW) derived from the National
Agreement for Home Labour Services (NAHLS)
[25] (this study considered only caregivers). Three
studies used a Daily Temporary Indemnity for
Professional Illness (DTIPI) [29,37,38], six used
either Gross National Salary (GNS) [24,27,32,34,39]
or the real wages of the sample of patients in-
cluded in the study [26].
To underline the large difference between pa-
rameters, the values of a working day lost used in
 
Table 1
 
Studies reviewed
 
Patients Caregivers
Reference Disease Type of study E N E N Value of a working day* Parameter of valuation
22 Prostatic hyperplasia CA X underivable GDP per capita
23 Alzheimer’s disease CA X 47.8 Assumptions
24 Major depression CA X X 100.2 GNS per capita
25 Alzheimer’s disease CA X 83.7 MW from the NAHLS
26 Hepatitis A CA X X 31.5 Sample salary
27 Varicella CA X X 123.1 GNS per capita
28 Ovarian cysts CA X 34.8 NAV per capita
29 Asthma CA X 103.3 DTIPI
30 Measles CA X 85.7 GRP per capita
31 Cancer CA X X 38.7 Assumptions
32 Tuberculosis CA X 79.2 GNS per capita
33 Leukemia CUA X 120.1 Assumptions
34 Teaching on asthma CEA/CBA X 79.2 GNS per capita
35 Pertussis vaccination CEA/CBA X X 80.2 Literature
36 Hepatitis B CBA X X 31.9 GNP per capita
37 Asthma CA X 103.3 DTIPI
38 Epilepsy CA X X 103.3 DTIPI
39 Schizophrenia CA X X 101.5 GNS per capita
40 Flu CA X 96.0 GDP per capita
 
*All values are expressed in Euro-Exchange rate/$ 
 

 
 0,9461.
CA, cost analysis; CBA, cost-benefit analysis; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DTIPI, daily temporary indemnity for professional illness; E,
employed; GDP, gross domestic product; GNP, gross national product; GNS, gross national salary; GRP, gross regional product; MW, minimum wage; N, nonem-
ployed; NAHLS, National Agreement for Home Labour Services; NAV, national added value.
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each article are reproduced in Table 1. We could
not estimate the value for one study [22]. Since
five studies did not specify them explicitly [23,24,
26–28], we recalculated them from results and ta-
bles presented in the articles. When studies re-
ported only annual data, we divided them by 220
(the annual working days by contract in Italy) to
derive the value of a working day. As it is shown
in Table 1, values are different even in articles that
referred to the same parameter of valuation for
the same year, that is, GNS. Unfortunately, the
method for assessing the working day lost de-
scribed in these articles did not allow us to explain
these differences.
In 13 studies [23–26,28–30,32,34,37–40] the
general methodology used was clear and repro-
ducible, in 4 [22,31,33,36] it was only partially
clear, and in 2 [27,35] it was not clear at all.
 
Italian Expert Survey
 
Out of 30 pharmacoeconomics experts, 25 re-
turned the questionnaire giving a response rate of
83%. The results of the survey are summarized in
Table 2. Of the 25 responders, 15 economists and
10 noneconomists, 23 had conducted at least one
economic evaluation, and 11 of them had quanti-
fied indirect costs. These responders stated they
had included indirect costs in a total of 47 studies.
This large number differs significantly from that
of studies eligible for the literature review—only
19. This difference may reflect the following situa-
tions:
• unpublished studies;
• studies published before 1992 that could not
have been captured by the search;
• studies conducted jointly by the responders—7
of the 15 publications reviewed were con-
ducted by at least two experts included in the
survey sample;
• articles published in minor Italian journals
hardly ever included in databases.
Nine of the 11 responders who conducted eco-
nomic evaluations including indirect costs used
the HCA and two the HSV, while none calculated
indirect costs with the FCM. 20 out of 25 re-
sponders considered it important to include indi-
rect costs in economic evaluations, justifying their
position as follows:
• indirect costs give more complete information
on the burden of health care interventions;
• time has an economic value that has to be con-
sidered;
• it is a relevant variable for measuring the social
costs of decisions in the health care sector.
Among these, 8 responders mentioned HSV as
the best method for calculating indirect costs, 2
HCA, and 3 the FCM, while 7 responders did not
answer. This is not consistent with the methods
actually described in the literature review. The dif-
ficulties of obtaining HSV and FCM estimates are
likely to be the major impediment to its use in
practice.
The last two questions were related to pharma-
ceutical policy, focusing on the importance of in-
direct costs in pharmacoeconomic studies from
the viewpoint of health authorities. Fifty-six per-
cent of those interviewed (14 out of 25) stated that
the health authorities should require indirect costs.
However, all of them specified that the require-
ment needs to be firmly justified and should not be
a binding recommendation; indirect costs are to be
clearly separated from direct ones. Most of these
experts (11 out of 14) would include indirect cost
estimates in drug-pricing calculations.
The sample of responders could be divided into
economists and noneconomists. Hence, we tested
for statistical differences in the answers from these
 
Table 2
 
Survey results
 
Questions Yes No
No
answer
Number of studies 
carried out
HCA FCM HSV
No
answer0 1 2 3 4 5 10
Have you ever conducted pharmacoeconomics studies? 23 2 0
If yes, in how many studies did you include indirect costs? 12 1 3 1 3 1 2
If indirect costs included, which method(s) did you use? 9 0 2 0
In your opinion, is it important to include indirect costs? 20 4 1
If yes, what is the best method for calculating indirect costs? 2 3 8 7
From the Italian health authorities viewpoint, is it important to
include indirect costs? 14 9 2
If yes, would you take indirect costs into consideration in the
pharmaceutical pricing process? 11 3 0
 
FCM, Friction Cost Method; HCA, Human Capital Approach; HSV, Health State Valuation.
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two groups. At the 5% significance level no dif-
ference was found to be statistically significant
(Fisher’s exact test).
 
Discussion
 
The number of economic evaluations of pharma-
ceuticals is growing rapidly, as are their relevance.
In Italy pharmacoeconomics has gained impor-
tance since the CUF listed this as one of the sub-
jects to be considered in submitting approval dos-
siers for innovative drugs [16]. Also, the CIPE
mentions cost-effectiveness ratios as a main crite-
rion for pricing negotiations of innovative drugs
[2]. However, public health authorities have not
yet issued official guidelines.
Indirect costs are a considerable part of the eco-
nomic burden of diseases and should be carefully
taken into account. However, the methods so far
developed to assess these costs show some weak-
nesses. Accordingly, we found that also Italian
pharmacoeconomists are far from any consensus
on including indirect cost and on the best method
for evaluating them.
The literature review showed that only a small
proportion of pharmacoeconomic studies in Italy
evaluated indirect costs. Although all studies used
the HCA, the practical methods adopted varied
widely. Sometimes the methods were not com-
pletely clear with respect to the estimation of pro-
ductive time lost, though it was fairly clear how it
was assessed. Variability in the parameters chosen
to monetize loss of production (e.g., GDP, GRP,
GNS) makes it hard to compare the results and
underlines the fact that Italian investigators do not
follow any common criteria for assessing indirect
costs.
The survey produced some interesting results.
First of all, it confirmed that many experts are not
used to evaluating indirect costs. However, many of
them acknowledged the importance of taking indi-
rect costs into account. When asked about the pre-
ferred method for evaluating indirect costs, many
responders mentioned HSV. This is not confirmed
by the results of the literature review and could be
taken as evidence of the difficulties of applying in
practice the methods for evaluating indirect costs
developed in the literature. Only 56% of the re-
sponders stated that health authorities should re-
quire indirect cost evaluations; most of them would
include indirect cost estimates in drug-pricing calcu-
lation. This would suggest that the Italian scientific
community is far from achieving any consensus on
how to use indirect costs in pharmaceutical pricing.
 
Conclusion
 
Pharmacoeconomics is still a young discipline
with many methodological weaknesses. Efforts
have been made to try to include indirect costs in
economic evaluations, but their incorporation is
still often neglected. Italy is no exception and does
not differ from most European countries where
this issue has still to be addressed properly, from
both the methodological and the practical stand-
points. Studies evaluating indirect costs are still
few, although there is evidence of an increase.
Moreover, the methods adopted need to be stan-
dardized, particularly with respect to the parame-
ters used for monetizing productive time lost. To
increase the impact of pharmacoeconomic studies
and their credibility for informing decision mak-
ing, an effort to reach a consensus on methods for
evaluating indirect costs seems desirable.
Given the lack of consensus on the methodol-
ogy along with the current framework of the Ital-
ian National Health Service, further research on
productivity issues is needed to provide relevant
information to the public health authorities.
 
Special thanks go to Judy Baggott and Clara Chiantaretto
for editing the manuscript, and to Paola De Compadri
for literature search.
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